FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1992908731> ?p ?o ?g. }

• W1992908731 endingPage "343" @default.
• W1992908731 startingPage "337" @default.
• W1992908731 abstract "<h3>Background</h3> Clozapine shows superior efficacy in schizophrenia and enhances prefrontal dopamine (DA) output like other atypical, but not typical, antipsychotic drugs (APDs). Clinical data also suggest an improved effect of typical APDs in schizophrenia by adjunctive treatment with low doses of 3,4-dihydroxyphenylalanine (L-dopa), but experimental support is scarce, and the underlying mechanisms are poorly understood. <h3>Methods</h3> Antipsychotic efficacy of the D₂ antagonist raclopride with or without adjunctive treatment with a low dose of L-dopa was assessed with the conditioned avoidance response paradigm. Extrapyramidal side effects were scored by the catalepsy test. Finally, in vivo microdialysis was used to measure DA efflux in the prefrontal cortex and the nucleus accumbens. <h3>Results</h3> A low dose of L-dopa (3 mg/kg) combined with benserazide, an inhibitor of peripheral DOPA decarboxylase, significantly enhanced the antipsychotic-like effect of raclopride without any associated catalepsy. L-dopa/benserazide alone had no effect. In contrast to raclopride alone, combined L-dopa/raclopride also produced a much larger increase in DA output in the prefrontal cortex than in the nucleus accumbens. <h3>Conclusions</h3> These data support the clinical observation that low-dose L-dopa might improve the effect of typical APDs in schizophrenia and indicate that increased prefrontal DA output per se enhances the antipsychotic effect of typical APDs." @default.
• W1992908731 created "2016-06-24" @default.
• W1992908731 creator A5024105514 @default.
• W1992908731 creator A5041566927 @default.
• W1992908731 creator A5071012889 @default.
• W1992908731 date "2005-08-01" @default.
• W1992908731 modified "2023-10-03" @default.
• W1992908731 title "Enhanced Cortical Dopamine Output and Antipsychotic-like Effect of Raclopride with Adjunctive Low-Dose L-dopa" @default.
• W1992908731 cites W112532169 @default.
• W1992908731 cites W14947124 @default.
• W1992908731 cites W1616286551 @default.
• W1992908731 cites W1755010820 @default.
• W1992908731 cites W1962326193 @default.
• W1992908731 cites W1967443916 @default.
• W1992908731 cites W1971179661 @default.
• W1992908731 cites W1972301638 @default.
• W1992908731 cites W1972498750 @default.
• W1992908731 cites W1972803223 @default.
• W1992908731 cites W1979236896 @default.
• W1992908731 cites W1982556596 @default.
• W1992908731 cites W1982786179 @default.
• W1992908731 cites W1986995142 @default.
• W1992908731 cites W1995778321 @default.
• W1992908731 cites W1996327177 @default.
• W1992908731 cites W1999389706 @default.
• W1992908731 cites W1999898236 @default.
• W1992908731 cites W2002664886 @default.
• W1992908731 cites W2005466129 @default.
• W1992908731 cites W2010341693 @default.
• W1992908731 cites W2021223587 @default.
• W1992908731 cites W2021489201 @default.
• W1992908731 cites W2025498375 @default.
• W1992908731 cites W2025771147 @default.
• W1992908731 cites W2032134562 @default.
• W1992908731 cites W2032866243 @default.
• W1992908731 cites W2036424845 @default.
• W1992908731 cites W2049059433 @default.
• W1992908731 cites W2052344160 @default.
• W1992908731 cites W2053786099 @default.
• W1992908731 cites W2057969745 @default.
• W1992908731 cites W2060277614 @default.
• W1992908731 cites W2068026066 @default.
• W1992908731 cites W2072069319 @default.
• W1992908731 cites W2076704115 @default.
• W1992908731 cites W2077760177 @default.
• W1992908731 cites W2080015973 @default.
• W1992908731 cites W2083680124 @default.
• W1992908731 cites W2090404564 @default.
• W1992908731 cites W2099185967 @default.
• W1992908731 cites W2100440324 @default.
• W1992908731 cites W2104465880 @default.
• W1992908731 cites W2106352416 @default.
• W1992908731 cites W2113469959 @default.
• W1992908731 cites W2115062882 @default.
• W1992908731 cites W2126720336 @default.
• W1992908731 cites W2133602373 @default.
• W1992908731 cites W2142151511 @default.
• W1992908731 cites W2150760506 @default.
• W1992908731 cites W2156240157 @default.
• W1992908731 cites W2157092444 @default.
• W1992908731 cites W2163738170 @default.
• W1992908731 cites W2163815564 @default.
• W1992908731 cites W2165843693 @default.
• W1992908731 cites W2169664308 @default.
• W1992908731 cites W2169909859 @default.
• W1992908731 cites W2262493346 @default.
• W1992908731 cites W2339914498 @default.
• W1992908731 cites W2406335305 @default.
• W1992908731 cites W2409427968 @default.
• W1992908731 cites W2413293679 @default.
• W1992908731 cites W2415111926 @default.
• W1992908731 cites W2416670973 @default.
• W1992908731 cites W3011905127 @default.
• W1992908731 cites W3015549329 @default.
• W1992908731 cites W32423411 @default.
• W1992908731 doi "https://doi.org/10.1016/j.biopsych.2005.03.038" @default.
• W1992908731 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/16102547" @default.
• W1992908731 hasPublicationYear "2005" @default.
• W1992908731 type Work @default.
• W1992908731 sameAs 1992908731 @default.
• W1992908731 citedByCount "20" @default.
• W1992908731 countsByYear W19929087312012 @default.
• W1992908731 countsByYear W19929087312013 @default.
• W1992908731 countsByYear W19929087312016 @default.
• W1992908731 countsByYear W19929087312017 @default.
• W1992908731 crossrefType "journal-article" @default.
• W1992908731 hasAuthorship W1992908731A5024105514 @default.
• W1992908731 hasAuthorship W1992908731A5041566927 @default.
• W1992908731 hasAuthorship W1992908731A5071012889 @default.
• W1992908731 hasConcept C118552586 @default.
• W1992908731 hasConcept C126322002 @default.
• W1992908731 hasConcept C15744967 @default.
• W1992908731 hasConcept C169760540 @default.
• W1992908731 hasConcept C169900460 @default.
• W1992908731 hasConcept C2776412080 @default.
• W1992908731 hasConcept C2776552330 @default.
• W1992908731 hasConcept C2779026782 @default.
• W1992908731 hasConcept C2779134260 @default.

• next